Guinea Resilience System

REUTERS by Kate Keller and Ben Hirschler                                      June 17, 2015

LONDON --Drugmakers' plans to conduct vast clinical trials to test and hopefully validate the first Ebola vaccines have been thwarted by success in beating back the deadly epidemic in West Africa.

GlaxoSmithKline, Merck and Johnson & Johnson are struggling to recruit volunteers with enough exposure to the disease to prove whether their vaccines are doing the job and preventing infection.

The story might have been very different with just another three or four months of disease spread, underscoring the need to act more quickly to develop vaccines for emerging diseases....

Guinea, where Ebola is still infecting new victims, as "the only hope" for showing efficacy, according to Kieny and to Adrian Hill, director of the Jenner Institute at Britain's Oxford University.

The WHO is overseeing the so-called ring vaccination study in Guinea in which close contacts and family around each new case of Ebola are vaccinated -- either immediately or after a three-week delay -- to see if the shot offers protection.

Read complete story.

THE WORLD BANK                                                                       June 15, 2015

WASHINGTON—Employment in Sierra Leone has returned to pre-crisis levels, though earnings and hours worked still lag behind. This is according to respondents in the latest round of high-frequency mobile-phone surveys, led by Statistics Sierra Leone with support from the World Bank Group, assessing how Ebola is impacting people’s livelihoods.

The survey contacted a sample of 1,715 households during May, 2015, which represents 41 percent of the 4,199 households covered in the baseline, nationally-representative Labor Force Survey conducted in July and August 2014.

 “Sierra Leone is working tirelessly to get to zero cases of Ebola,” said Francis Ato Brown, World Bank Group Country Manager for Sierra Leone. “Our job has to be not only to support the country in eradicating Ebola, but also to look toward economic recovery and toward mitigating the short-, medium-, and long-term impacts of the crisis on the social and economic wellbeing of all Sierra Leoneans.”

THE LANCET byMichel Van Herp, Hilde Declerck and Tom Decroo June 13, 2015

.. the efficacy of candidate Ebola vaccines for primary prevention has not been proven.² Furthermore, in communities in which Ebola transmission might be ongoing, an important question is: how will such a vaccination be perceived if a vaccinated person develops Ebola? Such a scenario is possible in people who contract Ebola virus before vaccination. If a person is infected with Ebola virus before vaccination, the vaccine might have a post-exposure prophylactic effect. However, how effective this prophylaxis might be is unknown.² Moreover, if someone is infected more than 48 h before vaccination, the post-exposure prophylactic effect is likely to be insufficient, leading to possible development of Ebola after vaccination. This scenario is likely to result in serious issues relating to community trust and acceptance of an Ebola vaccine.³ How to exclude Ebola among people presenting with post-vaccination fever is also an issue.²

PUBLIC BROADCASTING CORP by Caleb Hellerman         June 11, 2015

The quest for an Ebola vaccine has been a journey filled with excruciating delays and mad dashes. The latest outbreak in West Africa caused governments and drug companies to jumpstart research that had languished back when the threat of Ebola wasn’t big enough to sustain a commercial market. (Prior to 2013, the virus had sickened fewer than 2,300 people in known history). Human safety trials of two vaccines began last summer — each being given to a small group of healthy volunteers. When no major side effects were apparent, health officials scrambled to launch larger tests in the countries that were most affected by Ebola.

A volunteer receives an Ebola vaccine in Sierra Leone. Thousands of these voluntary immunizations have been tested so far in the West African nation. Photo by Cameron Hickey.